Atypical Subtrochanteric Femoral Fractures in Patients with Skeletal Malignant Involvement Treated with Intravenous Bisphosphonates

Puhaindran, Mark E.; Farooki, Azeez; Steensma, Matthew R.; Hameed, Meera; Healey, John H.; Boland, Patrick J.
July 2011
Journal of Bone & Joint Surgery, American Volume;7/6/2011, Vol. 93-A Issue 13, p1235
Academic Journal
Background: Atypical subtrochanteric femoral fractures have been identified as a potential complication of long-term bisphosphonate therapy for the treatment of osteoporosis. Patients with skeletal malignant involvement, who receive much higher cumulative doses of bisphosphonates than do patients with osteoporosis, may be at higher risk for the development of these fractures. Methods: A retrospective review of the imaging studies and case notes was done for patients with skeletal malignant involvement who received a minimum of twenty-four doses of intravenous bisphosphonates between 2004 and 2007 and were followed until death or the time of the latest review. Patients were classified as having an atypical subtrochanteric femoral fracture if they had a transverse subtrochanteric fracture following low-energy trauma or an impending fracture, together with radiographic findings of diffuse diaphyseal cortical thickening and cortical beaking at the subtrochanteric area. Results: In the study cohort of 327 patients, we identified four patients who developed an atypical subtrochanteric femoral fracture. All four patients were female, three had breast cancer, and one had myeloma. There was no significant difference between patients who developed an atypical subtrochanteric femoral fracture and those who did not with regard to the doses of intravenous bisphosphonates or the duration of treatment. Conclusions: The prevalence of atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement who are managed with high doses of intravenous bisphosphonates is low. All patients in our study who had development of these fractures had prodromal symptoms of thigh pain. Level of Evidence: Prognostic Level IV. See Instructions to Authors for a complete description of levels of evidence.


Related Articles

  • Potential new drug treatment for osteoporosis.  // Bulletin of the World Health Organization;2000, Vol. 78 Issue 1, p144 

    Reports on the potential use of statins as drug treatment for osteoporosis discovered by Greg Mundy and colleagues in the United States. Restrictions on current treatments; Bone restoration effects of statins.

  • Raloxifene and Osteoporosis.  // American Family Physician;9/15/1999, Vol. 60 Issue 4, p1139 

    Presents information on the link between raloxifene and osteoporosis. Major cause of osteoporosis; How to avoid osteoporosis; How raloxifene helps prevent osteoporosis.

  • Compliance crucial for fracture prevention in osteoporosis.  // PharmacoEconomics & Outcomes News;8/18/2012, Issue 660, p3 

    The article discusses research on the clinical and economic burden of bisphosphonates in patients with osteoporosis medications in Ireland, referencing a study by M. Hiligsmann and colleagues published in the July 2012 issue of "Value in Health."

  • Drugs in the News.  // Clarendon Enterprise (TX);10/5/2006, Vol. 17 Issue 42, p8 

    The article reports that Novartis has tested its Reclast-branded zoledronic acid for postmenopausal osteoporosis. The role of the drug in reducing spine and hip fractures is emphasized. A description of the side effects of the drug is presented. An overview of other drugs for osteoporosis...

  • Risedronate. Goa, K.L.; Balfour, J.A. // Drugs & Aging;1998, Vol. 13 Issue 1, p83 

    â–´ Risedronate is a pyridinyl bisphosphonate that can be administered orally in lower dosages than other antiresorptive bisphosphonates. Like others of its class risedronate inhibits osteoclast-mediated bone resorption. â–´ In experimental models of osteoporosis, risedronate inhibited...

  • Denosumab for osteoporosis.  // Clinical Cardiology Alert;Nov2009 Clinical Briefs, p22 

    The article discusses research on the use of denosumab against osteoporosis. It references a study by S. R. Cummings et al published in a 2009 issue of the "New England Journal of Medicine." According to the study involving nearly 8,000 osteoporotic women, women taking the drug had up to sixty...

  • New practice guideline for osteoporosis. Elliott, William T. // Primary Care Reports;Nov2008 Pharmacology Watch, p2 

    The article focuses on the Clinical Practice Guideline regarding the pharmacologic treatment of patients with low bone density or osteoporosis, which was issued by the American College of Physicians. According to the 2008 issue of the "Annals of Internal Medicine," the expert committee suggests...

  • Investigation and treatment of osteoporosis in patients with fragility fractures. Hajcsar, Ernest E.; Hawker, Gillian; Bogoch, Earl R. // CMAJ: Canadian Medical Association Journal;10/03/2000, Vol. 163 Issue 7, p819 

    AbstractBackground: Many patients who have undiagnosed osteoporosis and a recent fragility fracture present to fracture clinics in Canadian hospitals, where the focus of management is on fracture care. The rate of diagnosis and treatment of osteoporosis in this patient group is unknown.Methods:...

  • Osteoprotective Effect of Enalapril, Losartan and Resveratrol in Experimental Osteoporosis. Faitelson, A. V.; Gudyrev, O. S.; Dubrovin, G. M.; Pokrovsky, M. V.; Ivanov, A. V.; Rajkumar, D. S. R. // Journal of Bioanalysis & Biomedicine;2012, Vol. 4 Issue 2, p30 

    Osteoporosis (OP) - a systemic skeletal disease characterized by low bone mass per unit volume and an impairment of the micro architecture of bone tissue, leading to an increase in bone fragility and a high risk of fractures. The basic cause of development of osteoporosis is an imbalance between...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics